Biopharmaceutical giant Eli Lilly raised full-year guidance after reporting a 26% year-over-year revenue rise in its 1st quarter. Led by sales of obesity & diabetes drugs, Eli Lilly’s chart has flirted with all-time highs. The Chart Master Rick Ducat takes a look at the stock’s uptrend.
30 Apr 2024
SHARE